X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 16.4 25.3 64.7% View Chart
P/BV x 3.7 2.7 137.7% View Chart
Dividend Yield % 1.1 0.5 235.6%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
SUN PHARMA
Mar-18
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs558701 79.7%   
Low Rs362433 83.4%   
Sales per share (Unadj.) Rs116.3110.4 105.3%  
Earnings per share (Unadj.) Rs17.911.0 162.8%  
Cash flow per share (Unadj.) Rs23.117.2 134.3%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.80.4 215.8%  
Book value per share (Unadj.) Rs85.4158.8 53.8%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.05.1 77.0%   
Avg P/E ratio x25.751.6 49.8%  
P/CF ratio (eoy) x19.932.9 60.4%  
Price / Book Value ratio x5.43.6 150.8%  
Dividend payout %19.618.2 107.5%   
Avg Mkt Cap Rs m470,6641,360,021 34.6%   
No. of employees `00011.817.8 66.4%   
Total wages/salary Rs m18,54553,671 34.6%   
Avg. sales/employee Rs Th10,072.714,890.9 67.6%   
Avg. wages/employee Rs Th1,569.13,017.1 52.0%   
Avg. net profit/employee Rs Th1,547.71,480.6 104.5%   
INCOME DATA
Net Sales Rs m119,049264,895 44.9%  
Other income Rs m1,1328,388 13.5%   
Total revenues Rs m120,181273,282 44.0%   
Gross profit Rs m28,47556,081 50.8%  
Depreciation Rs m5,38814,998 35.9%   
Interest Rs m9115,176 17.6%   
Profit before tax Rs m23,30844,295 52.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m5,6448,452 66.8%   
Profit after tax Rs m18,29226,338 69.5%  
Gross profit margin %23.921.2 113.0%  
Effective tax rate %24.219.1 126.9%   
Net profit margin %15.49.9 154.5%  
BALANCE SHEET DATA
Current assets Rs m82,005316,359 25.9%   
Current liabilities Rs m60,720198,643 30.6%   
Net working cap to sales %17.944.4 40.2%  
Current ratio x1.41.6 84.8%  
Inventory Days Days7395 77.1%  
Debtors Days Days98108 91.3%  
Net fixed assets Rs m83,703213,178 39.3%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m86,421378,606 22.8%   
Net worth Rs m87,445381,006 23.0%   
Long term debt Rs m25,55117,721 144.2%   
Total assets Rs m180,653643,028 28.1%  
Interest coverage x26.69.6 278.1%   
Debt to equity ratio x0.30 628.2%  
Sales to assets ratio x0.70.4 160.0%   
Return on assets %10.64.9 216.9%  
Return on equity %20.96.9 302.6%  
Return on capital %22.010.0 219.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68340,816 104.6%   
Fx outflow Rs m11,24230,143 37.3%   
Net fx Rs m31,44110,673 294.6%   
CASH FLOW
From Operations Rs m9,19339,072 23.5%  
From Investments Rs m-9,737-33,708 28.9%  
From Financial Activity Rs m515-15,393 -3.3%  
Net Cashflow Rs m-29-7,359 0.4%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 20, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS